Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.

Cellular and molecular life sciences : CMLS - 25 May 2024

Sui Fang, Wang Guanjie, Liu Juan, Yuan Mengmeng, Chen Pu, Yao Yao, Zhang Shaoqiang, Ji Meiju, Hou Peng

Abstract excerpt

BRAFV600E represents a constitutively active onco-kinase and stands as the most prevalent genetic alteration in thyroid cancer. However, the clinical efficacy of small-molecule inhibitors targeting BRAFV600E is often limited by acquired resistance. Here, we find that nerve/glial antigen 2 (NG2), also known as chondroitin sulfate proteoglycan 4 (CSPG4), is up-regulated in thyroid cancers, and its expression is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens
Share to Chondroitin Sulfate Proteoglycans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Phenylurea Compounds

Share to Proteoglycans

Share to Quinolines

Share to Sorafenib

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 38795180
DOI: 10.1007/s00018-024-05280-6
PMCID: PMC11127897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.PMID 38795180Read ↗

SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibitionSemantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?Semantic proximity Read ↗

Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Semantic proximity Read ↗

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.Semantic proximity Read ↗

The serine-threonine kinase TAO3 promotes cancer invasion and tumor growth by facilitating trafficking of endosomes containing the invadopodia scaffold TKS5αSemantic proximity Read ↗

STMN2/NF-κB axis drives tumor growth in thyroid carcinomaSemantic proximity Read ↗

Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.Semantic proximity Read ↗

Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib.Semantic proximity Read ↗

Tspan2: a tetraspanin protein involved in oligodendrogenesis and cancer metastasisSemantic proximity Read ↗

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.Semantic proximity Read ↗

Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.